USS Investment Management Ltd Has $4.14 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

USS Investment Management Ltd trimmed its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 28.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,149 shares of the biopharmaceutical company's stock after selling 64,457 shares during the quarter. USS Investment Management Ltd's holdings in Royalty Pharma were worth $4,135,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in RPRX. Allworth Financial LP boosted its holdings in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 877 shares during the period. Riverview Trust Co lifted its position in shares of Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,186 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 997 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Royalty Pharma by 160.5% in the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 1,003 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 376 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on RPRX shares. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Finally, Morgan Stanley started coverage on shares of Royalty Pharma in a research report on Friday, May 16th. They issued an "overweight" rating and a $51.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $42.50.

Royalty Pharma Stock Up 0.4%

NASDAQ:RPRX traded up $0.14 during mid-day trading on Friday, reaching $32.45. The stock had a trading volume of 2,514,291 shares, compared to its average volume of 3,476,979. The business's 50 day moving average is $32.40 and its 200 day moving average is $30.22. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.32. The stock has a market cap of $18.71 billion, a P/E ratio of 22.38, a PEG ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. As a group, sell-side analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.71%. Royalty Pharma's dividend payout ratio is currently 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.